Lupifil-P

Reduction in duration of neutropenia & incidence of febrile neutropenia in patients treated w/ cytotoxic chemotherapy for malignancy (w/ exception of chronic myeloid leukemia & myelodysplastic syndromes).

SC Adult 6 mg as single inj once per chemotherapy cycle.

Known hypersensitivity or history of serious allergic reactions to pegfilgrastim, filgrastim, E. coli derived proteins.

Serious allergic reactions including anaphylaxis. Not to be administered in patients w/ history of serious allergic reactions to pegfilgrastim or filgrastim; between 14 days before & 24 hr after administration of cytotoxic chemotherapy. Not to be used to increase dose of cytotoxic chemotherapy beyond established dose regimen; in myelodysplastic syndrome, chronic myelogenous leukaemia, & secondary AML. Discontinue treatment immediately if leukocyte counts exceed 50 x 10⁹/L after expected nadir; in patients w/ acute resp distress syndrome; permanently in patients w/ serious allergic reactions. Splenic rupture. Severe sickle cell crises in patients w/ sickle cell disorders receiving treatment. Potential for tumor growth stimulatory effects on malignant cells. Patients receiving high dose chemotherapy w/ AML. Contains sorbitol. Perform WBC count at regular intervals during therapy. Carefully monitor spleen size. Evaluate patients who report left upper abdominal &/or shoulder tip pain for enlarged spleen or splenic rupture; who develop fever & lung infiltrates or resp distress after receiving treatment. Not to be taken by patients w/ rare hereditary problems of fructose intolerance. Pregnancy. Not to be used during breastfeeding. Childn & adolescents <18 yr.

Headache; nausea; bone & musculoskeletal pain (myalgia, arthralgia, extremity, back, musculoskeletal & neck pain). Thrombocytopenia; inj site reaction (including inj site pain & erythema), non-cardiac chest pain.

Potentiated myelosuppression w/ 5-fluorouracil or other antimetabolites. Transient +ve bone imaging changes. Potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy; administer at least 24 hr after cytotoxic chemotherapy.

Haematopoietic Agents

L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.

S